newsfilter
← Latest News
GlobeNewswire·

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

Achieved three major catalysts to drive future growth: Launched the pediatric indication of Afrezza® following FDA approvalFUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and CKDPositive